论文部分内容阅读
我院近几年来，采用广东天普生物化学制药有限公司生产的“天普洛欣”（高纯度注射用尿激酶）治疗急性心肌梗死（AMI）68例，取得满意效果，现报告如下。1资料与方法一股资料：68例中，男46例，女22例，年龄38～66岁。均符合WHO规定的AMI诊断标准，并具备下列条件：①严重胸闷
Our hospital in recent years, the use of Guangdong Temple Pharmaceutical Biotechnology Co., Ltd. produced “Temporoxin” (high purity injection of urokinase) in the treatment of 68 cases of acute myocardial infarction (AMI), and achieved satisfactory results are as follows. 1 Materials and Methods 1 Information: 68 cases, 46 males and 22 females, aged 38 to 66 years. All meet the WHO diagnostic criteria for AMI, and have the following conditions: ① severe chest tightness